Hirokazu Ikeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hirokazu Ikeda has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Tsuneki Watanabe
Children’s Medical Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Japan
24 shared publications- Yoshitaka Watanabe
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
22 shared publications Yuta Onuki
Children’s Medical Center, Showa Medical University Northern Yokohama Hospital, Yokohama, Japan
12 shared publications- Masaki Fuyama
Department of Pediatrics Showa Medical University Fujigaoka Hospital Yokohama Kanagawa Japan
10 shared publications Chisato Oyake
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
9 shared publicationsTakahiro Ono
Children's Medical Center Showa Medical University Northern Yokohama Hospital Yokohama Kanagawa Japan
9 shared publications
Latest Publications
- 9 October 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (5) , 283
Exploratory analysis of electroencephalogram activity preceding nocturnal enuresis episodes using home-based sleep monitoring
- 9 October 2026
- Published by Springer Nature in Sleep and Breathing
- Vol. 30 (5) , 283
Exploratory analysis of electroencephalogram activity preceding nocturnal enuresis episodes using home-based sleep monitoring
- Open Access
- 1 October 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (10) , 415
Clinical characteristics, antimicrobial therapy, and outcomes in febrile infants with and without human parechovirus detected in cerebrospinal fluid
Background: Human parechovirus (HPeV) infection in infants aged ®︎ meningitis/encephalitis panel has been reimbursed by national health insurance system since September 2022, but its clinical utility for the management of febrile young infants has not yet been well characterized in the Japanese clinical setting. Therefore, we compared the clinical characteristics and outcomes of febrile infants with and without HPeV detection using the FilmArray® meningitis/encephalitis panel. Methods: Between April and November 2023, 25 febrile infants aged ® meningitis/encephalitis panel. In this retrospective cohort study, patients were classified into HPeV-positive (n=9) and HPeV-negative (n=16) groups based on HPeV detection in CSF using the panel. Clinical symptoms, physical findings, laboratory data, duration of antimicrobial therapy, and length of hospital stay were retrospectively extracted from medical records. The Wilcoxon two-sample test and Fisher’s exact test were used for between-group comparisons. Results: The median ages were 31 and 37 days in the HPeV-positive and HPeV-negative groups, respectively. There were no significant differences in age, sex, or other baseline characteristics between the two groups. Compared with the HPeV-negative group, the HPeV-positive group more frequently exhibited abdominal distension (78% vs. 6%, Pvs. 13%, P=0.009), and palmar-plantar erythema (44% vs. 0%, P=0.01). At admission, white blood cell counts (median, 4,310 vs. 9,090 /μL, P=0.02) and C-reactive protein levels (0.24 vs. 0.91 mg/dL, P=0.01) were significantly lower in the HPeV-positive group. Although the duration of fever tended to be longer in the HPeV-positive group (48 vs. 30 hours, P=0.13), the duration of antimicrobial therapy was significantly shorter (62 vs. 85 hours, P=0.02). No significant difference was observed in the length of hospital stay (6 vs. 7 days, P=0.09). Conclusions: In this small, single-center study, HPeV-positive febrile infants received a shorter duration of antimicrobial therapy than HPeV-negative infants. Rapid identification of HPeV using the FilmArray® meningitis/encephalitis panel may support appropriate antimicrobial use in febrile young infants. However, HPeV detection alone does not exclude bacterial infection, and larger studies are needed to determine the impact of rapid HPeV identification on antimicrobial management.
- 1 October 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (10) , 415
Open AccessClinical characteristics, antimicrobial therapy, and outcomes in febrile infants with and without human parechovirus detected in cerebrospinal fluid
Background: Human parechovirus (HPeV) infection in infants aged ®︎ meningitis/encephalitis panel has been reimbursed by national health insurance system since September 2022, but its clinical utility for the management of febrile young infants has not yet been well characterized in the Japanese clinical setting. Therefore, we compared the clinical characteristics and outcomes of febrile infants with and without HPeV detection using the FilmArray® meningitis/encephalitis panel. Methods: Between April and November 2023, 25 febrile infants aged ® meningitis/encephalitis panel. In this retrospective cohort study, patients were classified into HPeV-positive (n=9) and HPeV-negative (n=16) groups based on HPeV detection in CSF using the panel. Clinical symptoms, physical findings, laboratory data, duration of antimicrobial therapy, and length of hospital stay were retrospectively extracted from medical records. The Wilcoxon two-sample test and Fisher’s exact test were used for between-group comparisons. Results: The median ages were 31 and 37 days in the HPeV-positive and HPeV-negative groups, respectively. There were no significant differences in age, sex, or other baseline characteristics between the two groups. Compared with the HPeV-negative group, the HPeV-positive group more frequently exhibited abdominal distension (78% vs. 6%, Pvs. 13%, P=0.009), and palmar-plantar erythema (44% vs. 0%, P=0.01). At admission, white blood cell counts (median, 4,310 vs. 9,090 /μL, P=0.02) and C-reactive protein levels (0.24 vs. 0.91 mg/dL, P=0.01) were significantly lower in the HPeV-positive group. Although the duration of fever tended to be longer in the HPeV-positive group (48 vs. 30 hours, P=0.13), the duration of antimicrobial therapy was significantly shorter (62 vs. 85 hours, P=0.02). No significant difference was observed in the length of hospital stay (6 vs. 7 days, P=0.09). Conclusions: In this small, single-center study, HPeV-positive febrile infants received a shorter duration of antimicrobial therapy than HPeV-negative infants. Rapid identification of HPeV using the FilmArray® meningitis/encephalitis panel may support appropriate antimicrobial use in febrile young infants. However, HPeV detection alone does not exclude bacterial infection, and larger studies are needed to determine the impact of rapid HPeV identification on antimicrobial management.
- Open Access
- 24 September 2026
- Published by Wiley in Neurourology and Urodynamics
Association Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study
Aims: Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1‐year treatment outcomes in children with NE. Methods: We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non‐CR groups based on 1‐year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi‐square test, Mann–Whitney U test, and multivariate logistic regression. Results: The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Conclusions: Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.
- 24 September 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessAssociation Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study
Aims: Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1‐year treatment outcomes in children with NE. Methods: We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non‐CR groups based on 1‐year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi‐square test, Mann–Whitney U test, and multivariate logistic regression. Results: The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Conclusions: Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (9) , 359
Beyond biochemical recovery: rethinking liver dysfunction in Kawasaki disease
Beyond biochemical recovery: rethinking liver dysfunction in Kawasaki disease
- 1 September 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (9) , 359
Open AccessBeyond biochemical recovery: rethinking liver dysfunction in Kawasaki disease
Beyond biochemical recovery: rethinking liver dysfunction in Kawasaki disease
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (8) , 332
A multicenter prospective evaluation of a decision chart for toilet training initiation
Background: There are currently no widely accepted standardized guidelines for determining the optimal timing to initiate toilet training in children. This study aimed to develop and evaluate the effectiveness of a newly designed tool—the Toilet Training Initiation Decision Chart (TTIDC). Methods: This multicenter, prospective, open-label intervention study included children aged ≥18 months attending 70 nursery schools. Participants were divided into an intervention group, which utilized the TTIDC, and a control group, which followed conventional toilet training practices employed by each school. Weekly observation records were collected from July 1, 2022 to June 30, 2023. The primary endpoints were the duration of toilet training and the age at which toilet training was completed. The TTIDC was developed based on a prior pilot study. Results: Of the 354 children enrolled, 43 completed toilet training during the study period. There was no significant correlation between the age of toilet training initiation and the duration required to complete training. However, the median age at completion was significantly younger in the intervention group (37.5 months) compared with the control group (40.8 months; P=0.002). Conclusions: This chart may serve as an effective tool for initiating toilet training at an appropriate developmental stage. This chart may be associated with completion of toilet training at a younger age, without prematurely accelerating initiation or unnecessarily prolonging the process.
- 1 August 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (8) , 332
Open AccessA multicenter prospective evaluation of a decision chart for toilet training initiation
Background: There are currently no widely accepted standardized guidelines for determining the optimal timing to initiate toilet training in children. This study aimed to develop and evaluate the effectiveness of a newly designed tool—the Toilet Training Initiation Decision Chart (TTIDC). Methods: This multicenter, prospective, open-label intervention study included children aged ≥18 months attending 70 nursery schools. Participants were divided into an intervention group, which utilized the TTIDC, and a control group, which followed conventional toilet training practices employed by each school. Weekly observation records were collected from July 1, 2022 to June 30, 2023. The primary endpoints were the duration of toilet training and the age at which toilet training was completed. The TTIDC was developed based on a prior pilot study. Results: Of the 354 children enrolled, 43 completed toilet training during the study period. There was no significant correlation between the age of toilet training initiation and the duration required to complete training. However, the median age at completion was significantly younger in the intervention group (37.5 months) compared with the control group (40.8 months; P=0.002). Conclusions: This chart may serve as an effective tool for initiating toilet training at an appropriate developmental stage. This chart may be associated with completion of toilet training at a younger age, without prematurely accelerating initiation or unnecessarily prolonging the process.
- Open Access
- 1 July 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (8) , 639-645
Association between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease
Background: Intravenous immunoglobulin (IVIG) formulations used to treat Kawasaki disease differ markedly in sodium content; however, the clinical significance of this factor remains unclear.Purpose: Here we investigated whether sodium content influences electrolyte changes and short-term clinical outcomes of Kawasaki disease.Methods: This single-center retrospective cohort study included 744 children with first-episode Kawasaki disease treated with 2-kg IVIG in 2010–2020. The patients were categorized into high-sodium (Glovenin-I or Venilon-I) and low-sodium (Venoglobulin IH) groups. Serum electrolytes, total protein, and immunoglobulin G levels were measured before and after IVIG administration. Outcomes included additional IVIG administration and the presence of coronary artery lesions.Results: Compared to the low-sodium group, the high-sodium group had significantly increased serum sodium (2.9±3.2 mEq/L vs. 1.7±2.7 mEq/L) but significantly decreased serum potassium (-0.13±0.50 mEq/L vs. -0.03±0.49 mEq/L) levels after IVIG therapy. After its administration, hyponatremia occurred more often in the low-sodium group (4.4% vs. 0.3%), whereas hypokalemia occurred more frequently in the high-sodium group (9.9% vs. 5.5%). Total protein, immunoglobulin G, and albumin levels were higher in the low-sodium group. The rates of additional IVIG use and coronary artery lesions did not differ significantly between groups.Conclusion: Our findings demonstrate that the sodium content of IVIG contributes to distinct changes in electrolyte and protein concentrations during the acute phase of Kawasaki disease. However, these biochemical differences were not associated with short-term clinical outcomes. Awareness of formulation-specific profiles may help clinicians interpret laboratory findings appropriately during IVIG therapy.
- 1 July 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (8) , 639-645
Open AccessAssociation between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease
Background: Intravenous immunoglobulin (IVIG) formulations used to treat Kawasaki disease differ markedly in sodium content; however, the clinical significance of this factor remains unclear.Purpose: Here we investigated whether sodium content influences electrolyte changes and short-term clinical outcomes of Kawasaki disease.Methods: This single-center retrospective cohort study included 744 children with first-episode Kawasaki disease treated with 2-kg IVIG in 2010–2020. The patients were categorized into high-sodium (Glovenin-I or Venilon-I) and low-sodium (Venoglobulin IH) groups. Serum electrolytes, total protein, and immunoglobulin G levels were measured before and after IVIG administration. Outcomes included additional IVIG administration and the presence of coronary artery lesions.Results: Compared to the low-sodium group, the high-sodium group had significantly increased serum sodium (2.9±3.2 mEq/L vs. 1.7±2.7 mEq/L) but significantly decreased serum potassium (-0.13±0.50 mEq/L vs. -0.03±0.49 mEq/L) levels after IVIG therapy. After its administration, hyponatremia occurred more often in the low-sodium group (4.4% vs. 0.3%), whereas hypokalemia occurred more frequently in the high-sodium group (9.9% vs. 5.5%). Total protein, immunoglobulin G, and albumin levels were higher in the low-sodium group. The rates of additional IVIG use and coronary artery lesions did not differ significantly between groups.Conclusion: Our findings demonstrate that the sodium content of IVIG contributes to distinct changes in electrolyte and protein concentrations during the acute phase of Kawasaki disease. However, these biochemical differences were not associated with short-term clinical outcomes. Awareness of formulation-specific profiles may help clinicians interpret laboratory findings appropriately during IVIG therapy.
- Open Access
- 17 May 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (7) , 1192-1199
Relationships of Early Parenteral Nutrition and Human Milk Fortification on the Growth of Neonates With Birth Weights Between 1500 and 1750 g
Introduction: Low‐birthweight infants have high nutrient requirements; however, early parenteral nutrition (EPN) and human milk fortification (HF) are provided in very low‐birthweight infants. We changed the indications for EPN and HF from very low birth weight to birth weight < 1750 g in our hospital in April 2019. Aim: This study aimed to assess the growth and neurodevelopmental relationships in infants with birth weights between 1500 and 1750 g, with or without EPN and HF. Methods: A retrospective cohort study was conducted using the medical records of infants with birth weights between 1500 and 1750 g from April 2016 to March 2022, who were divided into two groups: before and after the change in indication. Results: EPN and HF promoted head circumference expansion during hospitalization. However, no relationships on growth were noted after hospital discharge. Furthermore, no difference in the incidence of complications was observed among the preterm infants, and relatively few adverse events associated with EPN and HF led to safe nutritional management. Conclusion: For infants with birth weights between 1500 and 1750 g, EPN and HF may improve short‐term growth, but may not have an impact in the long term.
- 17 May 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (7) , 1192-1199
Open AccessRelationships of Early Parenteral Nutrition and Human Milk Fortification on the Growth of Neonates With Birth Weights Between 1500 and 1750 g
Introduction: Low‐birthweight infants have high nutrient requirements; however, early parenteral nutrition (EPN) and human milk fortification (HF) are provided in very low‐birthweight infants. We changed the indications for EPN and HF from very low birth weight to birth weight < 1750 g in our hospital in April 2019. Aim: This study aimed to assess the growth and neurodevelopmental relationships in infants with birth weights between 1500 and 1750 g, with or without EPN and HF. Methods: A retrospective cohort study was conducted using the medical records of infants with birth weights between 1500 and 1750 g from April 2016 to March 2022, who were divided into two groups: before and after the change in indication. Results: EPN and HF promoted head circumference expansion during hospitalization. However, no relationships on growth were noted after hospital discharge. Furthermore, no difference in the incidence of complications was observed among the preterm infants, and relatively few adverse events associated with EPN and HF led to safe nutritional management. Conclusion: For infants with birth weights between 1500 and 1750 g, EPN and HF may improve short‐term growth, but may not have an impact in the long term.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70504
A Rare Case of Kawasaki Disease Complicating Poststreptococcal Acute Glomerulonephritis
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70504
A Rare Case of Kawasaki Disease Complicating Poststreptococcal Acute Glomerulonephritis